Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.
Earnings and Valuation
This table compares Cartesian Therapeutics and Syndax Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cartesian Therapeutics | $1.48 million | 145.01 | -$130.30 million | ($5.94) | -1.19 |
| Syndax Pharmaceuticals | $172.35 million | 8.73 | -$285.42 million | ($2.51) | -6.76 |
Volatility and Risk
Cartesian Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
Profitability
This table compares Cartesian Therapeutics and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cartesian Therapeutics | -8,550.65% | N/A | -29.84% |
| Syndax Pharmaceuticals | -87.52% | -372.94% | -39.11% |
Analyst Ratings
This is a summary of current ratings and target prices for Cartesian Therapeutics and Syndax Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Syndax Pharmaceuticals | 1 | 0 | 10 | 0 | 2.82 |
Cartesian Therapeutics currently has a consensus price target of $32.60, indicating a potential upside of 360.52%. Syndax Pharmaceuticals has a consensus price target of $41.80, indicating a potential upside of 146.17%. Given Cartesian Therapeutics’ higher possible upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than Syndax Pharmaceuticals.
Institutional & Insider Ownership
86.9% of Cartesian Therapeutics shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Cartesian Therapeutics beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
